share_log

Pfizer | SC TO-I: Issuer tender offer statement

Pfizer | SC TO-I: Issuer tender offer statement

輝瑞 | SC TO-I:投標報價單
美股SEC公告 ·  08/12 11:46

Moomoo AI 已提取核心訊息

Pfizer Inc. has announced a voluntary Modification Offer for eligible employees holding performance share awards (PSAs) and total shareholder return units (TSRUs) granted in 2022 and 2023. The offer, which commenced on August 12, 2024, allows participants to modify their existing equity awards, extending the performance period by two years with adjusted terms. The offer aims to retain key talent by enhancing the incentive and retention value of these awards, following a decline in Pfizer's stock price which impacted the potential achievement of performance goals. The offer is open until 11:59 p.m., Eastern Time, on September 12, 2024, unless extended. Eligible participants include current active employees who have been continuously employed since July 24, 2024. The offer does not apply to independent board members. Pfizer's executive officers, including the CEO, are eligible to participate. The offer is not conditioned on a minimum number of acceptances and is subject to certain conditions outlined by the company. Pfizer's common stock is traded on the NYSE under the symbol 'PFE'.
Pfizer Inc. has announced a voluntary Modification Offer for eligible employees holding performance share awards (PSAs) and total shareholder return units (TSRUs) granted in 2022 and 2023. The offer, which commenced on August 12, 2024, allows participants to modify their existing equity awards, extending the performance period by two years with adjusted terms. The offer aims to retain key talent by enhancing the incentive and retention value of these awards, following a decline in Pfizer's stock price which impacted the potential achievement of performance goals. The offer is open until 11:59 p.m., Eastern Time, on September 12, 2024, unless extended. Eligible participants include current active employees who have been continuously employed since July 24, 2024. The offer does not apply to independent board members. Pfizer's executive officers, including the CEO, are eligible to participate. The offer is not conditioned on a minimum number of acceptances and is subject to certain conditions outlined by the company. Pfizer's common stock is traded on the NYSE under the symbol 'PFE'.
輝瑞公司宣佈了一項自願修改計劃,適用於2022年和2023年獲授業績股份獎勵(PSA)和總股東回報單位(TSRU)的合格員工。該計劃從2024年8月12日開始,允許參與者修改現有股權獎勵,將業績期限延長兩年,並作出相應調整。該計劃旨在通過增加這些獎勵的激勵和留任價值,留住關鍵人才,因爲輝瑞的股價下跌影響了業績目標的達成。該計劃開放至2024年9月12日美國東部時間晚上11:59,除非延期。符合條件的參與者包括自2024年7月24日起不間斷僱用的在職員工。該計劃不適用於獨立董事會成員。輝瑞的高管,包括CEO,有資格參加該計劃。該計劃不受最低接受數量的限制,並受公司規定的某些條件的限制。輝瑞普通股在紐交所上市,標的爲「PFE」。
輝瑞公司宣佈了一項自願修改計劃,適用於2022年和2023年獲授業績股份獎勵(PSA)和總股東回報單位(TSRU)的合格員工。該計劃從2024年8月12日開始,允許參與者修改現有股權獎勵,將業績期限延長兩年,並作出相應調整。該計劃旨在通過增加這些獎勵的激勵和留任價值,留住關鍵人才,因爲輝瑞的股價下跌影響了業績目標的達成。該計劃開放至2024年9月12日美國東部時間晚上11:59,除非延期。符合條件的參與者包括自2024年7月24日起不間斷僱用的在職員工。該計劃不適用於獨立董事會成員。輝瑞的高管,包括CEO,有資格參加該計劃。該計劃不受最低接受數量的限制,並受公司規定的某些條件的限制。輝瑞普通股在紐交所上市,標的爲「PFE」。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息